SARS-CoV-2 Vaccine development: Current Status
Date
2020Author
Poland, Gregory A.
Ovsyannikova, Inna G.
Crooke, Stephen N.
Kennedy, Richard B.
Metadata
Show full item record
Documentos PDF
Imagenes y Videos
Abstract
In the midst of the SARS-CoV-2 pandemic and its attendant morbidity and mortality, safe
and efficacious vaccines are needed that induce protective and long-lived immune responses.
Over 120 vaccine candidates worldwide are in various preclinical, and phase I-III clinical trials
that include inactivated, live attenuated, viral vectored replicating and non-replicating), protein
and peptide-based, and nucleic acid approaches. Vaccines will be necessary both for individual
protection and for the safe development of population-level herd immunity. Public-private
partnership collaborative efforts, such as the Accelerating COVID-19 Therapeutic Interventions
and Vaccines (ACTIV) mechanism, are key to rapidly identifying safe and effective vaccie
candidates as quickly and efficiently as possible. In this article, we review the major vaccine
approaches being taken and issues that must be resolved in the quest for vaccines to prevent
COVID-19.
We scanned the PubMed database from 1963–2020 for all publications using the
following search terms in various combinations: SARS, MERS, COVID-19, SARS-CoV-2,
vaccine, clinical trial, coronavirus, pandemic, vaccine development. We also did a web search
for these same terms. We also examined the World Health Organization, Centers for Disease
Control and Prevention, and other public health authority websites. We excluded abstracts and
all articles that were not written in English.
Link to resource
https://doi.org/10.1016/j.mayocp.2020.07.021Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.